ARTICLE | Company News
Amorcyte, NeoStem deal
October 24, 2011 7:00 AM UTC
NeoStem completed its acquisition of cardiovascular company Amorcyte in a stock deal. NeoStem plans to begin a Phase II trial of Amorcyte's lead candidate, AMR-001, to treat acute myocardial infarcti...